A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions
about
Therapy of human papillomavirus-related diseaseRole of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasiaOrchestration of angiogenesis by immune cellsNucleotide variation in IL-10 and IL-12 and their receptors and cervical and vulvar cancer risk: a hybrid case-parent triad and case-control study.Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.hrHPV E5 oncoprotein: immune evasion and related immunotherapies.Local lymphocytes and nitric oxide synthase in the uterine cervical stroma of patients with grade III cervical intraepithelial neoplasia.Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus.Obesity adversely affects survival in pancreatic cancer patients.CD28-, CD45RA(null/dim) and natural killer-like CD8+ T cells are increased in peripheral blood of women with low-grade cervical lesions.Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients.Immune therapy for human papillomaviruses-related cancers.Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion DevelopmentLiposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch.Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies.Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer.Peripheral blood lymphocytes from low-grade squamous intraepithelial lesions patients recognize vaccine antigens in the presence of activated dendritic cells, and produced high levels of CD8 + IFNγ + T cells and low levels of IL-2 when induced to prCytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls.Immunotherapy of human papilloma virus induced diseaseNew approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer.Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma.Substantial increase in the frequency of circulating CD4+NKG2D+ T cells in patients with cervical intraepithelial neoplasia grade 1.Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.Expression of interleukin-5 and tumor necrosis factor alpha in cervical carcinoma.Analysis of the Prevalence of HTLV-1 Proviral DNA in Cervical Smears and Carcinomas from HIV Positive and Negative Kenyan Women.Moving forward with human papillomavirus immunotherapies.Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesionsNatural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence.The relationship between the antitumor effect of the IL-12 gene therapy and the expression of Th1 cytokines in an HPV16-positive murine tumor model.Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeoverThe interplay between HPV and host immunity in head and neck squamous cell carcinoma.Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers.Immune Modulation and Treatment of Human Papilloma Virus-Related Warts with Energetics of Living Systems Acupuncture.Increased TNF-alpha and sTNFR2 levels are associated with high-grade anal squamous intraepithelial lesions in HIV-positive patients with low CD4 level.The Neutrophil-Lymphocyte Ratio Predicts Recurrence of Cervical Intraepithelial Neoplasia.Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection.Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer.Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.Concentration levels of IL-10 and TNFα cytokines in patients with human papilloma virus (HPV) DNA⁺ and DNA⁻ cervical lesions.
P2860
Q27007473-B0F0442B-8BA9-476F-B040-33D0C9EBD8BAQ27010447-1BC33E6D-BEF5-45E3-B2AE-0FC00E2E3F10Q28389236-751308E4-BD68-4867-B033-7D8757CA025FQ30557445-E2F86874-72C8-4DF3-9381-85345888298DQ33620823-F426ADF8-BAA4-4AC6-9920-12D671AB1861Q33730462-D47E339C-753A-4F36-AA4F-0BBDBDA90B6BQ33967828-EBAB2389-C298-482E-87DC-678007254773Q34159707-C77E0156-7494-459D-B076-984CFFB67616Q34238737-27D7D745-2202-41FD-B87F-2150322B583EQ34270848-18B17DFF-3B2B-4F15-83EC-E1E3CA849729Q34453827-08B9ECAB-B997-4B3F-AB4F-05C513489FFDQ34657561-E11D86E4-DDD9-4416-B123-44F0555509C1Q35636308-72E9FFC1-D992-46C4-94C5-00714BFBFD69Q35750626-424D6110-8887-45FA-A19B-3E8384C20009Q35777091-6E5C37C0-5429-49A5-87CF-EC3FB28C24FDQ35778017-00661175-F7B9-4420-AA6F-0810E7EBB717Q35871517-B8FBF7A8-018D-4B0C-87E4-B48B0E8A2728Q36123196-CA928DCC-5FEC-4A09-9DC3-0F6E971C4D81Q36417513-BE1CB96F-08CD-41E1-9F79-FF40397FEB5AQ36541008-093FC60C-60DE-4995-8A5B-8489A26CEC19Q36877132-136913A2-A32E-45DE-B3C2-F5A1D7D5A329Q36947101-2D200C80-A275-4DD1-9840-63A9E63F9E7DQ37116995-805B208E-0EBA-43D3-A93B-D9598805151BQ37135023-14F6A83C-48DA-4C4B-AC1F-79F6930994BAQ37213884-FBE80DFD-9ECB-4D6E-B156-681C2C911C0EQ37281763-884CBEB4-CCFD-408D-9C46-66E2E97D42DDQ37473299-8387C2F5-89B6-484D-ABF2-B07091CC8E4BQ37511930-A8D215F7-DED3-435E-B6F2-955A9A99AF56Q37604535-BC24416C-A51A-47B7-A296-15747CEAD242Q37720469-465CEC07-99EB-46CB-83F0-F96B37E53F3CQ37723390-2E4FCF39-8109-4E68-9001-DB018857F8C2Q38126455-472528EE-E252-49D8-9E1E-75D4CCDEFC85Q38363737-12CAF016-5E6B-4FFD-8A96-F8F0C0EBFED9Q40111267-D4D03C47-EDE5-44FE-A29A-732990843B65Q40129526-4B562748-D022-48D1-B012-38EE25C0D2A8Q41440982-9CE3C3FF-FFF8-4738-A747-06AC2AF7BA49Q42283665-BB77919D-8F72-42FC-8B9E-D9F6A28492D3Q42380313-386E5100-7FBF-4388-8251-583A99B99F19Q44280889-2FD62C49-F43D-4266-8EFE-CA1F91DD4E3CQ45358593-BCA20CDC-5E5B-4238-BF64-113F5824224A
P2860
A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A shift to a peripheral Th2-ty ...... es manifest in CIN III lesions
@ast
A shift to a peripheral Th2-ty ...... es manifest in CIN III lesions
@en
type
label
A shift to a peripheral Th2-ty ...... es manifest in CIN III lesions
@ast
A shift to a peripheral Th2-ty ...... es manifest in CIN III lesions
@en
prefLabel
A shift to a peripheral Th2-ty ...... es manifest in CIN III lesions
@ast
A shift to a peripheral Th2-ty ...... es manifest in CIN III lesions
@en
P2093
P2860
P356
P1476
A shift to a peripheral Th2-ty ...... es manifest in CIN III lesions
@en
P2093
Beckmann I
Helmerhorst TJ
Lindemans J
Snijders PJ
P2860
P304
P356
10.1136/JCP.2004.025072
P407
P577
2005-10-01T00:00:00Z